KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Operating Leases (2018 - 2026)

Moderna (MRNA) has disclosed Operating Leases for 9 consecutive years, with $664.0 million as the latest value for Q1 2026.

  • For Q1 2026, Operating Leases fell 2.64% year-over-year to $664.0 million; the TTM value through Mar 2026 reached $664.0 million, down 2.64%, while the annual FY2025 figure was $653.0 million, 2.68% down from the prior year.
  • Operating Leases hit $664.0 million in Q1 2026 for Moderna, up from $653.0 million in the prior quarter.
  • Across five years, Operating Leases topped out at $730.0 million in Q3 2023 and bottomed at $87.0 million in Q2 2022.
  • Average Operating Leases over 5 years is $472.8 million, with a median of $653.0 million recorded in 2025.
  • Year-over-year, Operating Leases decreased 25.0% in 2022 and then soared 598.91% in 2023.
  • Moderna's Operating Leases stood at $92.0 million in 2022, then surged by 598.91% to $643.0 million in 2023, then rose by 4.35% to $671.0 million in 2024, then fell by 2.68% to $653.0 million in 2025, then increased by 1.68% to $664.0 million in 2026.
  • According to Business Quant data, Operating Leases over the past three periods came in at $664.0 million, $653.0 million, and $660.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.